FDA approves drug for hemphilia A patients

The U.S. Food and Drug Administration approved Eloctate for use in adults and children who have hemophilia A.

Advertisement

Eloctate is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures and prevent or reduce the frequency of bleeding episodes.

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

Eloctate consists of the coagulation factor VIII molecule — historically known as antihemophilic factor — linked to a protein fragment, Fc, which is found in antibodies. The safety and efficacy of the drug was evaluated in a clinical trial of 164 patients.

More Articles on Quality:

Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.